BRII BIOSCIENCES LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.21 HKD | 0.00% |
|
-0.82% | -46.93% |
| Sales 2024 * | - | Sales 2025 * | 181M 24.94M 195M | Capitalization | 818M 113M 882M |
|---|---|---|---|---|---|
| Net income 2024 * | -528M -72.88M -569M | Net income 2025 * | -412M -56.87M -444M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 4.53 x |
| P/E ratio 2024 * |
-1.73
x | P/E ratio 2025 * |
-3.2
x | Employees | 128 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Brii Biosciences Limited
More press releases
| 1 week | -0.82% | ||
| Current month | +3.42% | ||
| 1 month | -4.72% | ||
| 3 months | +18.63% | ||
| 6 months | -52.36% | ||
| Current year | -46.93% |
1 week
1.16
1.27
1 month
1.161.50
Current year
0.852.39
1 year
0.854.20
3 years
0.8552.60
5 years
0.8552.60
10 years
0.8552.60
| Managers | Title | Age | Since |
|---|---|---|---|
Zhi Hong
CEO | Chief Executive Officer | 60 | 17-12-07 |
An Kang Li
DFI | Director of Finance/CFO | 47 | 20-08-31 |
David Margolis
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gregg Alton
BRD | Director/Board Member | 58 | 21-06-21 |
Tai Yin Yang
BRD | Director/Board Member | 70 | 22-08-31 |
Robert Nelsen
BRD | Director/Board Member | 60 | 18-06-21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.53% | 4 M€ | -27.92% | ||
| 0.00% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-05 | 1.21 | 0.00% | 492 500 |
| 24-06-04 | 1.21 | +2.54% | 398,000 |
| 24-06-03 | 1.18 | +0.85% | 607,500 |
| 24-05-31 | 1.17 | -0.85% | 912,500 |
| 24-05-30 | 1.18 | -3.28% | 1,060,500 |
Delayed Quote Hong Kong S.E., June 05, 2024 at 03:59 am EDT
More quotes
Brii Biosciences Ltd is a biotechnology company based in China and the United States principally engaged in developing therapies for infectious diseases. The Companyâs products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens. The Company is also developing therapies for COVID-19 and other diseases.
Calendar
2024-06-24
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.121
CNY
Average target price
5.536
CNY
Spread / Average Target
+393.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -46.93% | 113M | |
| +16.73% | 123B | |
| +13.04% | 107B | |
| -5.80% | 24.01B | |
| +2.18% | 22.59B | |
| -10.09% | 18.16B | |
| -40.52% | 16.84B | |
| -14.00% | 16.23B | |
| +1.18% | 13.43B | |
| +24.18% | 11.32B |
- Stock Market
- Equities
- 2137 Stock
